

**Cardiovascular Research**

<b>Heart Failure Trials</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
ANTHEM-HFrEF	Autonomic neural regulation therapy to enhance myocardial function in heart failure study	<a href="https://clinicaltrials.gov/ct2/show/NCT01823887?term=anthem-hf&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01823887?term=anthem-hf&amp;rank=1</a>
PRIORITIZE	Potassium reduction initiative to optimize RAAS inhibition therapy with sodium zirconium cyclosilicate in heart failure	<a href="https://clinicaltrials.gov/ct2/show/NCT03532009?term=d9484c00001&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03532009?term=d9484c00001&amp;rank=1</a>
SOLOIST-WHF	Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure	<a href="https://clinicaltrials.gov/ct2/show/NCT03521934?term=SOLOIST-WHF&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03521934?term=SOLOIST-WHF&amp;rank=1</a>
TRANSFORM HF	Torsemide comparison with furosemide for management of heart failure	<a href="https://clinicaltrials.gov/ct2/show/NCT03296813?term=TRANSFORM+HF&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03296813?term=TRANSFORM+HF&amp;rank=1</a>
DELIVER	Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure	<a href="https://clinicaltrials.gov/ct2/show/NCT03619213?term=D169CC00001&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03619213?term=D169CC00001&amp;rank=1</a>
EMPERIAL Reduced	This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms	<a href="https://clinicaltrials.gov/ct2/show/NCT03448419?term=EMPERIAL+Reduced&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03448419?term=EMPERIAL+Reduced&amp;rank=1</a>
EMPERIAL Preserved	This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms	<a href="https://clinicaltrials.gov/ct2/show/NCT03448406?term=EMPERIAL+Preserved&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03448406?term=EMPERIAL+Preserved&amp;rank=1</a>
ENVISAGE	Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation	<a href="https://clinicaltrials.gov/ct2/show/NCT02943785?term=ENVISAGE&amp;draw=1&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02943785?term=ENVISAGE&amp;draw=1&amp;rank=1</a>
GALACTIC	Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction	<a href="https://clinicaltrials.gov/ct2/show/NCT02929329?term=20110203&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02929329?term=20110203&amp;rank=1</a>
HEART-FID	Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency	<a href="https://clinicaltrials.gov/ct2/show/record/NCT03037931?term=1V1T15043&amp;rank=1">https://clinicaltrials.gov/ct2/show/record/NCT03037931?term=1V1T15043&amp;rank=1</a>
<b>Device Trials</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
APPRAISE ATP	Assessment of Primary Prevention Patients Receiving An ICD – Systematic Evaluation of ATP	<a href="https://clinicaltrials.gov/ct2/show/NCT02923726?term=APPRAISE+ATP&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02923726?term=APPRAISE+ATP&amp;rank=1</a>
CONFIDENCE	Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis	<a href="https://clinicaltrials.gov/ct2/show/study/NCT02657707?term=CL11003&amp;rank=1">https://clinicaltrials.gov/ct2/show/study/NCT02657707?term=CL11003&amp;rank=1</a>
JET-RANGER	JETStream Atherectomy with Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Balloon Angioplasty followed by Paclitaxel-Coated Balloon in Treating Complex Denovo Femoropopliteal Arterial Disease	<a href="https://clinicaltrials.gov/ct2/show/NCT03206762?term=JET-RANGER&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03206762?term=JET-RANGER&amp;rank=1</a>
SMART MSP	Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study	<a href="https://clinicaltrials.gov/ct2/show/NCT03257436?term=C1918&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03257436?term=C1918&amp;rank=1</a>
<b>General Cardiology</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
AEGIS-II	Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome	<a href="https://clinicaltrials.gov/ct2/show/NCT03473223?cond=CSL112&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03473223?cond=CSL112&amp;rank=1</a>
CLEAR Outcomes	Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo	<a href="https://clinicaltrials.gov/ct2/show/NCT02993406?term=1002-043&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02993406?term=1002-043&amp;rank=1</a>
NODE-301	Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT	<a href="https://clinicaltrials.gov/ct2/show/NCT03464019?term=NCT03464019&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03464019?term=NCT03464019&amp;rank=1</a>
NODE-302	Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT	<a href="https://clinicaltrials.gov/ct2/show/NCT03635996?term=node-302&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03635996?term=node-302&amp;rank=1</a>
PARADISE MI	Prospective ARNI vs ACE inhibitory trial to determine superiority in reducing heart failure events after MI.	<a href="https://clinicaltrials.gov/ct2/show/NCT02924727?term=CLCZ696G2301&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02924727?term=CLCZ696G2301&amp;rank=1</a>
TRAVERSE	A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events and efficacy measure in hypogonadal men	<a href="https://clinicaltrials.gov/ct2/show/NCT03518034?term=M16-100&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03518034?term=M16-100&amp;rank=1</a>

**Specialty Research**

<b>Type 2 Diabetes</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
------------------------	--------------------	--------------------------------

AZ T2D	A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes	<a href="https://clinicaltrials.gov/ct2/show/NCT01554618?term=D5551C00002&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01554618?term=D5551C00002&amp;rank=1</a>
DINAMO	Diabetes study of linagliptin and empagliflozin in children and adolescents	<a href="https://clinicaltrials.gov/ct2/show/NCT03429543?term=DINAMO&amp;rank=2">https://clinicaltrials.gov/ct2/show/NCT03429543?term=DINAMO&amp;rank=2</a>
PEDALon	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus	<a href="https://clinicaltrials.gov/ct2/show/NCT02856113?term=SYR-322_309&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02856113?term=SYR-322_309&amp;rank=1</a>
RVT-1501-1002	A Randomized, Phase 1b, Double-Blind, Placebo-Controlled, Parallel Arm Study to Assess the Safety, Tolerability, and Pharmacokinetics of RVT-1501 (imeglimin) in Subjects with Type 2 Diabetes Mellitus and Moderate to Severe Chronic Kidney Disease	N/A - phase 1 studies aren't required to be on clinicaltrials.gov

Type 1 Diabetes	Trial Title	ClinicalTrials.gov Link
TN-01	TrialNet Pathway to Prevention	<a href="https://clinicaltrials.gov/ct2/show/NCT00097292?term=TrialNet&amp;draw=1&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT00097292?term=TrialNet&amp;draw=1&amp;rank=1</a>
TN-16 (LIFT)	Long-Term investigative follow up in TrialNet	
C-Diff	Trial Title	ClinicalTrials.gov Link
PUNCH CD3	Microbiota restoration therapy for recurrent clostridium difficile infection	<a href="https://clinicaltrials.gov/ct2/show/NCT03244644?term=rbx2660&amp;rank=3">https://clinicaltrials.gov/ct2/show/NCT03244644?term=rbx2660&amp;rank=3</a>
Ri-CoDiFy-1	Comparison of Ridinazole versus vancomycin treatment for clostridium difficile infection	<a href="https://clinicaltrials.gov/ct2/show/NCT03595553?term=ri-codify-1&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03595553?term=ri-codify-1&amp;rank=1</a>
Kidney Disease	Trial Title	ClinicalTrials.gov Link
EMPA Kidney	The study of heart and kidney protection with empagliflozin	<a href="https://clinicaltrials.gov/ct2/show/NCT03594110?term=empa+kidney&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03594110?term=empa+kidney&amp;rank=1</a>
Influenza	Trial Title	ClinicalTrials.gov Link
IA-001	Exploring safety & clinical benefit of anti-influenza immunoglobulin intravenous in hospitalized adults with influenza A	<a href="https://clinicaltrials.gov/ct2/show/NCT03315104?term=IA-001&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03315104?term=IA-001&amp;rank=1</a>
Other	Trial Title	ClinicalTrials.gov Link
PMDx060	Clinical biospecimen procurement protocol to support advancements in medical diagnosis of diseases	N/A

## John T. Vucurevich Cancer Care Institute

Brain	Trial Title	ClinicalTrials.gov Link
Anaplastic Glioma (N0577)	Phase III Intergroup Study of Radiotherapy vs Temozolomide Alone vs Radiotherapy with Concomitant and Adjuvant Temozolomide for Patient with 1p19q Codeleted Anaplastic Glioma	<a href="https://clinicaltrials.gov/ct2/show/NCT00887146?id=n0577&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT00887146?id=n0577&amp;rank=1</a>
Breast	Trial Title	ClinicalTrials.gov Link
Node (+) (A011502)	A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For HER2 Negative Breast Cancer: The ABC Trial.	<a href="https://clinicaltrials.gov/ct2/show/NCT02927249?id=a011502&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02927249?id=a011502&amp;rank=1</a>
Metastatic /Advanced / Refractory (A171601)	A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer	<a href="https://clinicaltrials.gov/ct2/show/NCT03633331?id=a171601&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03633331?id=a171601&amp;rank=1</a>
Adjuvant/Node+ or HR Node- Triple Negative (BR003)	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node Negative Triple Negative Invasive Cancer	<a href="https://clinicaltrials.gov/ct2/show/NCT02488967?id=br003&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02488967?id=br003&amp;rank=1</a>
Adjuvant / ER + and/or PR+ (S1207)	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer e3 Breast Cancer Study- evaluating everolimus with endocrine therapy	<a href="https://clinicaltrials.gov/ct2/show/NCT01674140?id=s1207&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01674140?id=s1207&amp;rank=1</a>
Neo-Adjuvant Triple Negative (S1418)	A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor- Negative Breast Cancer with >=1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy	<a href="https://clinicaltrials.gov/ct2/show/NCT02954874?id=s1418&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02954874?id=s1418&amp;rank=1</a>

Adjuvant Triple Negative (WO39391/AFT-27)	Impassion 030, A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Standard Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer	<a href="https://clinicaltrials.gov/ct2/show/NCT03498716?id=wo39391&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03498716?id=wo39391&amp;rank=1</a>
Biomarkers (2018-01)	Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors	<a href="https://clinicaltrials.gov/ct2/show/NCT03662204?id=2018-01&amp;rank=9">https://clinicaltrials.gov/ct2/show/NCT03662204?id=2018-01&amp;rank=9</a>
Biomarkers (A011401)	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	<a href="https://clinicaltrials.gov/ct2/show/NCT02750826?id=a011401&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02750826?id=a011401&amp;rank=1</a>
Symptom Reporting (AFT-39/PRO-TECT)	Electronic Patient Reporting of Symptoms During Cancer Treatment	<a href="https://clinicaltrials.gov/ct2/show/NCT03249090?id=aft-39&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03249090?id=aft-39&amp;rank=1</a>
Brain (CC003)	A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer	<a href="https://clinicaltrials.gov/ct2/show/NCT02635009?id=cc003&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02635009?id=cc003&amp;rank=1</a>
<b>GI</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Colon - Adjuvant / Resected (A021502)	Randomized Trial of FOLFOX Alone or in Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC)	<a href="https://clinicaltrials.gov/ct2/show/NCT02912559?id=a021502&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02912559?id=a021502&amp;rank=1</a>
<b>GYN</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Ovarian / Peritoneal / Fallopian Tube/Endometrial (GY005)	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	<a href="https://clinicaltrials.gov/ct2/show/NCT02502266?id=gy005&amp;rank=2">https://clinicaltrials.gov/ct2/show/NCT02502266?id=gy005&amp;rank=2</a>
Ovarian / Peritoneal / Fallopian Tube/Endometrial (GY009)	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	<a href="https://clinicaltrials.gov/ct2/show/NCT02839707?id=gy009&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02839707?id=gy009&amp;rank=1</a>
<b>Hematologic</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Myelodysplastic Syndrome and Symptomatic Anemia (NHLBI-MDS)	The National Myelodysplastic Syndromes (MDS) Study	<a href="https://clinicaltrials.gov/ct2/show/NCT02775383?id=nhlbi-mds&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02775383?id=nhlbi-mds&amp;rank=1</a>
<b>Melanoma</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Locally Advanced/Metastatic (CTSUS1320)	Randomized Phase II Trial of Intermittent vs Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT02196181?id=s1320&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02196181?id=s1320&amp;rank=1</a>